Peter Johann
InvestorManaging General Partner at NGN Capital
About
Managing General Partner at NGN Capital with a background in biotech and pharmaceutical business development, having previously held senior corporate development, licensing, and marketing roles at Boehringer Ingelheim, F. Hoffmann-La Roche, and Boehringer Mannheim. He holds a Ph.D. from the Technical University Munich and serves on several life sciences company boards including Exosome Diagnostics and Vivaldi Biosciences.
Contact· self-published, not guessed
Invests in
Biotech
Investments
Board seats
Cerapedics, Inc.Endosense SAExosome Diagnostics Inc.Horizon Pharma IncJerini AGMicromet Inc.NaniRx TherapeuticsNoxxon Pharma AGResverlogix Corp.Santhera Pharmaceuticals AGVivaldi Biosciences, Inc.Zenith Epigenetics Inc.
Per the firm's website.
Colleagues at NGN Capital
Frequently asked questions
- Who is Peter Johann?
- Managing General Partner at NGN Capital with a background in biotech and pharmaceutical business development, having previously held senior corporate development, licensing, and marketing roles at Boehringer Ingelheim, F. Hoffmann-La Roche, and Boehringer Mannheim. He holds a Ph.D. from the Technical University Munich and serves on several life sciences company boards including Exosome Diagnostics and Vivaldi Biosciences.
- Where does Peter Johann work?
- Peter Johann is Managing General Partner at NGN Capital.
- What does Peter Johann invest in?
- Peter Johann invests in Biotech.
- What boards does Peter Johann sit on?
- Peter Johann holds tracked board seats at Cerapedics, Inc., Endosense SA, Exosome Diagnostics Inc., Horizon Pharma Inc, Jerini AG, Micromet Inc., NaniRx Therapeutics, Noxxon Pharma AG, Resverlogix Corp., Santhera Pharmaceuticals AG.